Saudi cinema re-opened six years ago in April 2018 after a 35-year hiatus. The sector has exploded with revenue during that period close to $1b, over 61 million tickets sold, 1,971 films screened including 45 local productions. Saudi-based director, producer and actor Todd Albert Nims joins The 966 to discuss the origins of the Saudi film sector, how it has transformed and what remains to be done. In addition to the recent 10th showing of the Saudi Film Festival, Todd examines other ongoing events (Cannes Film Festival, Red Sea International Film Festival, etc.) including the 2nd U.S.-Saudi Film Forum happening later this month.

William Greene, MD, Chief Investment Officer (CIO) of the Hevolution Foundation, joins The 966 to talk about Hevolution's investment strategy and role as an investor in the emerging field of Healthspan Science. As CIO, Dr. Greene oversees all aspects of Hevolution Foundation’s investment strategy, planning, analysis, and execution.

The Hevolution Foundation, based in Riyadh, is a non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science.

Last month, Hevolution announced its first ever impact investment to catalyze the healthspan and geroscience ecosystem and drive transformative breakthroughs in healthy aging.

Dr. William Greene’s leadership positions have included founder, biotechnology executive, investor, and clinician. As CEO, he built Iconic Therapeutics through discovery, clinical development and venture financing, leading to a successful sale of the company. He later helmed longevity biotech company Fountain Therapeutics and co-founded digital therapeutics startup Pear Therapeutics.

Dr. Greene spent 12 years at MPM Capital where he was a Managing Director and member of its Investment Committee, responsible for biotechnology and medical technology investments worldwide. He was also founding Chairman and head of the Investment Committee at the Global Health Investment Fund, a groundbreaking impact-oriented venture fund in collaboration with the Gates Foundation, which successfully scaled both investment returns and health impact simultaneously.

Earlier in his career, Dr. Greene was an Assistant Professor of Medicine at University of California at San Francisco (UCSF) and led clinical trials and strategy for a variety of therapeutic areas at Genentech.

Dr. Greene earned his BA from Wesleyan University and his MD from UCSF. He was a Robert Wood Johnson Clinical Scholar at Yale and a Howard Hughes Medical Institute Research Scholar at the US National Institutes of Health (NIH).

U.S. Ambassador to the Kingdom of Saudi Arabia Michael Ratney joins The 966 to talk diplomacy and U.S.-Saudi relations.

In recent years, he was the Acting Deputy Director of the U.S. Department of State’s training center, the Foreign Service Institute, where he had also been Dean of the State Department’s School of Language Studies. He was Chargé d’Affaires at the U.S. Embassy in Jerusalem in 2021, and earlier served on the faculty of the National Defense University.

Ambassador Ratney was the U.S. Special Envoy for Syria from 2015 to 2018, and also served as acting Deputy Assistant Secretary for the Levant and Israel and Palestinian Affairs. He was the U.S. Consul General in Jerusalem from 2012 to 2015, where he was responsible for U.S. relations with Palestinians in the West Bank, Gaza, and Jerusalem. He has been Deputy Assistant Secretary for International Media, overseeing a network of State Department media hubs throughout the world, and was Spokesman for the State Department’s Bureau of Near Eastern Affairs.